Ligue contre le cancer, France   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Paris France (1918)

Organization Overview

First Clinical Trial
2002
NCT00198432
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ligue contre le cancer, France

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthenia (Phase 3)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Diarrhea (Phase 2)

Glioblastoma (Phase 1)

Head and Neck Neoplasms (Phase 3)

Microsatellite Instability (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Nervous System Neoplasms (Phase 2)

Osteosarcoma (Phase 3)

Ovarian Neoplasms (Phase 2)

Penile Neoplasms (Phase 2)

Skin Neoplasms (Phase 2)

Thyroid Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 16